<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties manuscript?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-journal-id">7908424</journal-id><journal-id journal-id-type="pubmed-jr-id">4825</journal-id><journal-id journal-id-type="nlm-ta">J Infect</journal-id><journal-id journal-id-type="iso-abbrev">J Infect</journal-id><journal-title-group><journal-title>The Journal of infection</journal-title></journal-title-group><issn pub-type="ppub">0163-4453</issn><issn pub-type="epub">1532-2742</issn></journal-meta><article-meta><article-id pub-id-type="pmid">35288118</article-id><article-id pub-id-type="pmc">11018252</article-id><article-id pub-id-type="doi">10.1016/j.jinf.2022.03.009</article-id><article-id pub-id-type="manuscript">HHSPA1974200</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Invasive mould infections in patients from floodwater-damaged areas after hurricane Harvey &#x02013; a closer look at an immunocompromised cancer patient population</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wurster</surname><given-names>Sebastian</given-names></name><xref rid="A1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Paraskevopoulos</surname><given-names>Timotheos</given-names></name><xref rid="A1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Toda</surname><given-names>Mitsuru</given-names></name><xref rid="A2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Jiang</surname><given-names>Ying</given-names></name><xref rid="A1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Tarrand</surname><given-names>Jeffrey J.</given-names></name><xref rid="A3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Williams</surname><given-names>Samantha</given-names></name><xref rid="A2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Chiller</surname><given-names>Tom M.</given-names></name><xref rid="A2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Jackson</surname><given-names>Brendan R.</given-names></name><xref rid="A2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Kontoyiannis</surname><given-names>Dimitrios P.</given-names></name><xref rid="A1" ref-type="aff">a</xref><xref rid="CR1" ref-type="corresp">*</xref></contrib></contrib-group><aff id="A1"><label>a</label>Department of Infectious Diseases, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States</aff><aff id="A2"><label>b</label>Centers for Disease Control and Prevention, Mycotic Diseases Branch, Atlanta, GA, United States</aff><aff id="A3"><label>c</label>Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States</aff><author-notes><corresp id="CR1"><label>*</label>Corresponding author. <email>dkontoyi@mdanderson.org</email>, <email>sysaxton@mdanderson.org</email> (D.P. Kontoyiannis).</corresp></author-notes><pub-date pub-type="nihms-submitted"><day>26</day><month>3</month><year>2024</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>12</day><month>3</month><year>2022</year></pub-date><pub-date pub-type="pmc-release"><day>15</day><month>4</month><year>2024</year></pub-date><volume>84</volume><issue>5</issue><fpage>701</fpage><lpage>709</lpage><abstract id="ABS1"><title>SUMMARY</title><sec id="S1"><title>Objectives:</title><p id="P1">Extensive floodwater damage following hurricane Harvey raised concerns of increase in invasive mould infections (IMIs), especially in immunocompromised patients. To more comprehensively characterize the IMI landscape pre- and post-Harvey, we used a modified, less restrictive clinical IMI (mcIMI) definition by incorporating therapeutic-intent antifungal drug prescriptions combined with an expanded list of host and clinical features.</p></sec><sec id="S2"><title>Methods:</title><p id="P2">We reviewed 103 patients at MD Anderson Cancer Center (Houston, Texas), who lived in Harvey-affected counties and had mould-positive cultures within 12 months pre-/post-Harvey (36 and 67 patients, respectively). Cases were classified as proven or probable IMI (EORTC/MSG criteria), mcIMI, or colonization/contamination. We also compared in-hospital mortality and 42- day survival outcomes of patients with mcIMI pre-/post-Harvey.</p></sec><sec id="S3"><title>Results:</title><p id="P3">The number of patients with mould- positive cultures from Harvey-affected counties almost doubled from 36 pre- Harvey to 67 post- Harvey (<italic toggle="yes">p</italic> &#x0003c; 0.01). In contrast, no significant changes in (mc)IMI incidence post-Harvey nor changes in the aetiological mould genera were noted. However, patients with mcIMIs from flood affected areas had significantly higher in-hospital mortality (<italic toggle="yes">p</italic> = 0.01).</p></sec><sec id="S4"><title>Conclusions:</title><p id="P4">We observed increased colonization but no excess cases of (mc)IMIs in immunosuppressed cancer patients from affected areas following a large flooding event such as hurricane Harvey.</p></sec></abstract><kwd-group><kwd>Mould exposure</kwd><kwd>Floodwater damage</kwd><kwd>Invasive mould infections</kwd><kwd>Aspergillosis</kwd><kwd>Mucormycosis</kwd><kwd>Disease surveillance</kwd><kwd>Mortality</kwd></kwd-group></article-meta></front><body><sec id="S5"><title>Introduction</title><p id="P5">In August 2017, hurricane Harvey and historic scale of flooding devastated the Houston metropolitan area and adjacent counties. A survey amongst immunocompromised Houston area residents revealed that almost half of them engaged in home clean-up and mould remediation activities, often with no or suboptimal personal protective equipment.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> Although this observation raised the concern of extensive mould exposure of patients at risk for invasive mould infections (IMIs), prior research by our group at the University of Texas MD Anderson Cancer Center (MDACC) found no institution-wide increase in culture-documented IMIs after the hurricane.<sup><xref rid="R2" ref-type="bibr">2</xref></sup> As an increased use of voriconazole and amphotericin B was seen at MDACC in the 12 month- period following the hurricane,<sup><xref rid="R2" ref-type="bibr">2</xref></sup> there might have been a lower threshold for initiation of mould-active antifungal treatment or prophylaxis in high-risk patients and/or an increased incidence of infection events not meeting the conventional IMI definitions.</p><p id="P6">In order to provide a more comprehensive characterization of hurricane Harvey&#x02019;s impact on the IMI landscape, the U.S. Centers for Disease Control and Prevention (CDC) developed a modified clinical IMI (mcIMI) case definition based on an expanded set of host and clinical features combined with therapeutic-intent antifungal drug prescription. We herein applied this less-restrictive mcIMI case definition specifically to MDACC patients residing in Harvey-affected Texas counties.</p></sec><sec id="S6"><title>Methods</title><sec id="S7"><title>Ethics statement</title><p id="P7">This study was approved by the MDACC institutional review board. Patient consent was waived for anonymized chart review.</p></sec><sec id="S8"><title>Identification of mould- positive cultures</title><p id="P8">We used the Cerner Millennium Microbiology module of MDACC&#x02019;s laboratory information system to identify mould-positive cultures, including dimorphic fungi, within a 12-month period before and after hurricane Harvey. Multiple mould-positive cultures from the same patient within a 60-day period were considered a single case.</p></sec><sec id="S9"><title>Data filtering and chart review</title><p id="P9">The postal codes of the patients&#x02019; place of residence were compared against the Federal Emergency Management Agency (FEMA) Texas Hurricane Harvey map DR-4332-TX.<sup><xref rid="R3" ref-type="bibr">3</xref></sup> Counties designated &#x0201c;public assistance areas&#x0201d; at a minimum were considered &#x0201c;affected counties&#x0201d;. Records of patients living outside these areas were excluded and the remaining cases proceeded to an in-depth chart review, which included the following items: Demographic data (age, gender), place of residence (postal code, county, state), evidence of possible mould infection (mould-positive cultures, pathology specimens consistent with an IMI, positive serum galactomannan or beta-glucan tests, other non-culture biomarkers, IMI-related ICD-10 codes), clinical and radiological evidence of an IMI (clinical criteria specified in <xref rid="T1" ref-type="table">Table 1</xref>), cytopenia (neutropenia &#x0003c; 500/&#x003bc;L, lymphopenia &#x0003c; 1000/&#x003bc;L), cancer diagnosis, transplant history (solid organ transplant or hematopoietic stem cell transplant, including presence of graft-versus-host disease [GvHD]), other predisposing conditions (diabetes mellitus, autoimmune diseases, alcoholism and liver cirrhosis, hemochromatosis, cytomegalovirus infection, total parental nutrition), recent surgeries or injuries, use of corticosteroids or other immunosuppressive or cytotoxic medications, use of mould-active antifungals, hospitalization, ICU admission, and in-hospital mortality. Data were entered into an electronic case report form (RedCap platform) provided by the CDC, Mycotic Diseases Branch. In addition, 42-day mortality outcomes were recorded by the investigators.</p></sec><sec id="S10"><title>Determination of the date of incidence (DOI)</title><p id="P10">The DOI was defined as the earliest date of possible evidence of an IMI event, considering cultures and non-culture biomarkers, histopathological evidence, therapeutic-intent antifungal drug prescription, and ICD-10 billing codes indicating an IMI event. Cases with a DOI before September 1, 2017, were considered &#x0201c;pre-Harvey&#x0201d; and cases with a DOI on or after September 1, 2017 were considered &#x0201c;post-Harvey&#x0201d;, respectively. Of note, no patient had a DOI between the landfall of hurricane Harvey in Texas (August 26, 2017) and the second week of September 2017.</p></sec><sec id="S11"><title>Case adjudication</title><p id="P11">The probability of an IMI event was independently determined by two investigators. European Organization for Research and Treatment of Cancer &#x00026; Mycosis Study Group (EORTC/MSG) consensus definitions<sup><xref rid="R4" ref-type="bibr">4</xref></sup> were used to identify patients with proven or probable IMIs. In addition, we applied the CDC&#x02019;s expanded case definition to classify the remaining patients as either mcIMI cases or &#x0201c;patients not meeting IMI criteria&#x0201d; (colonization/contamination). Patients were classified as mcIMI cases if they received mould-active antifungal therapy after collection of a mould-positive specimen and additionally met at least one EORTC/MSG or non-EORTC/MSG clinical or host criterion (<xref rid="T1" ref-type="table">Table 1</xref>). One discordant adjudication was resolved by a joint review of the investigators.</p></sec><sec id="S12"><title>Hospital census</title><p id="P12">The following denominators were used to calculate incidence rates within a 12-month period pre- and post-Harvey, respectively: Number of inpatient hospital admissions, 28,793 pre-Harvey and 29,118 post-Harvey; number of inpatient days, 202,411 pre-Harvey and 207,071 post-Harvey.</p></sec><sec id="S13"><title>Statistical analyses</title><p id="P13">Categorical variables were compared using chi-square or Fisher&#x02019;s exact test. Continuous variables were compared using Kruskal-Wallis and Wilcoxon rank-sum tests for 3- and 2-group comparisons, respectively. If a significant result (<italic toggle="yes">p</italic> &#x0003c; 0.05) was detected for a 3-group comparison, pairwise comparisons were performed with <italic toggle="yes">&#x003b1;</italic> levels adjusted using Holm&#x02019;s sequential Bonferroni method. Poisson distribution and chi-square test were used to compare incidence rates of mould infections. Survival curves were estimated using the Kaplan-Meier method and compared with the Mantel-Cox log-rank test. All tests were 2-sided with a significance level of 0.05 except for pairwise comparisons with <italic toggle="yes">&#x003b1;</italic> adjustment. Statistical analyses and data visualization were performed using SAS version 9.3 (SAS Institute, Inc., Cary, NC), GraphPad Prism version 8 (GraphPad Software Inc., San Diego, USA), and Microsoft Excel.</p></sec></sec><sec id="S14"><title>Results</title><p id="P14">Four-hundred-and-four MDACC patients with mould-positive cultures between September 2016 (12 months pre-Harvey) and August 2018 (12 months post-Harvey) were identified using the institutional microbiology laboratory information system (<xref rid="SD1" ref-type="supplementary-material">Supplementary Data Set</xref>). A single mould genus was isolated from a single material in 329 out of these 404 patients. <italic toggle="yes">Aspergillus</italic> was the most commonly identified genus (<italic toggle="yes">n</italic> = 153, including 10 patients with multiple <italic toggle="yes">Aspergillus</italic> species). Nineteen patients had a single genus isolated from multiple respiratory samples and 8 patients had the same mould/genus isolated from multiple sites or materials. Thirty-one patients had two or more genera isolated from a single site or material. A total of 17 patients had multiple mould genera recovered from multiple respiratory samples or multiple sampling sites (<xref rid="SD1" ref-type="supplementary-material">Supplementary Data Set</xref>).</p><p id="P15">One-hundred-and-seven out of the 404 unique cases represented patients living in Harvey-affected areas ( <xref rid="F2" ref-type="fig">Fig. 2</xref>). Four out of these 107 patients were excluded from further analysis after chart review. Three patients had a mould-positive culture within the study period, but their finally determined DOI was more than 12 months prior to hurricane Harvey. In addition, one case of &#x0201c;sterile hyphae&#x0201d; recovered from a skin lesion was later identified as a proven yeast infection with no evidence of an IMI event and was excluded from analysis (<xref rid="F2" ref-type="fig">Fig. 2</xref>). After exclusions, 103 cases remained in the final analysis.</p><p id="P16">Notably, these 103 cases were not distributed evenly between the pre- and post-Harvey period. Instead, the number of patients with mould-positive cultures from Harvey-affected counties almost doubled from 36 pre-Harvey to 67 post-Harvey (<xref rid="F2" ref-type="fig">Fig. 2</xref>), resulting in a significantly increased incidence of positive cultures after the hurricane (<xref rid="F3" ref-type="fig">Fig. 3A</xref>, <italic toggle="yes">p</italic> &#x0003c; 0.01). Thirty-four out of the 67 patients with mould-positive cultures post-Harvey (51%) were adjudicated as having probable/proven IMIs (<italic toggle="yes">n</italic> = 11) or mcIMI (<italic toggle="yes">n</italic> = 23), compared to 23 (mc)IMI cases pre-Harvey (9 probable/proven IMIs and 14 mcIMI cases). The difference in incidence rates of probable/proven IMIs or mcIMI cases pre- and post-Harvey did not reach significance (<xref rid="F3" ref-type="fig">Fig. 3B</xref>, <italic toggle="yes">p</italic> = 0.15&#x02013; 0.18), whereas the incidence rate of patients with mould-positive cultures not meeting the IMI criteria significantly increased post-Harvey (<xref rid="F3" ref-type="fig">Fig. 3C</xref>, <italic toggle="yes">p</italic> &#x0003c; 0.01). Of note, 76% of mould-positive cultures in patients not meeting the IMI criteria were obtained from respiratory samples, suggesting increased asymptomatic colonization of respiratory epithelia.</p><p id="P17">Patients with probable/proven IMIs were more likely to have active leukaemia/myelodysplastic syndrome (<italic toggle="yes">p</italic> &#x0003c; 0.001) and/or severe neutropenia &#x0003c; 500/&#x003bc;L (<italic toggle="yes">p</italic> &#x0003c; 0.001) and to receive corticosteroids (<italic toggle="yes">p</italic> &#x0003c; 0.01) or other immunosuppressive therapies (<italic toggle="yes">p</italic> &#x0003c; 0.001) compared with mcIMI cases and patients not meeting the IMI definitions (<xref rid="T2" ref-type="table">Table 2</xref>). Patients with proven/probable IMIs had higher rates of extrapulmonary or disseminated mycoses and had a higher proportion of Mucorales or <italic toggle="yes">Fusarium</italic> spp. recovered as the causative agent than patients with mcIMIs (<xref rid="T2" ref-type="table">Table 2</xref>). Compared to patients not meeting the IMI definitions, a higher proportion of patients with probable/proven IMIs or mcIMIs received systemic antifungal therapy, such as liposomal amphotericin B or broad-spectrum triazoles (<italic toggle="yes">p</italic> &#x0003c; 0.001) (<xref rid="T2" ref-type="table">Table 2</xref>). Similarly, patients meeting at least the mcIMI definition more often required hospitalization (<italic toggle="yes">p</italic> &#x0003c; 0.001) or ICU admission (<italic toggle="yes">p</italic> = 0.03) and had higher in-hospital mortality (<italic toggle="yes">p</italic> = 0.05) than patients with mould-positive cultures but no clinical correlate (<xref rid="T2" ref-type="table">Table 2</xref>).</p><p id="P18">Comparing all patients from Harvey-affected counties with mould-positive cultures before and after the hurricane, no significant differences in demographics, predisposing factors, and outcomes were seen, except for a higher percentage of patients with a history of lymphopenia in the post-Harvey cohort (<xref rid="SD1" ref-type="supplementary-material">Table S1</xref>, <italic toggle="yes">p</italic> &#x0003c; 0.01). Restricting the comparison to patients with IMI or mcIMI events, no significant differences in baseline characteristics and predisposing factors were found between the pre- and post-Harvey cohorts (<xref rid="T3" ref-type="table">Table 3</xref>). Nonetheless, the percentage of hospitalized patients requiring ICU admission in the course of their (mc)IMI treatment increased from 30% pre-Harvey to 56% post-Harvey (<xref rid="T3" ref-type="table">Table 3</xref>, <italic toggle="yes">p</italic> = 0.06). Likewise, the percentage of patients with (mc)IMI dying in-hospital rose from 17% pre- Harvey to 50% (<italic toggle="yes">p</italic> = 0.01), whereas 42-day mortality (30% pre-Harvey versus 45% post-Harvey, <italic toggle="yes">p</italic> = 0.26) and survival curves (log-rank test, <italic toggle="yes">p</italic> = 0.18) did not significantly differ depending on the DOI (<xref rid="F4" ref-type="fig">Fig. 4</xref>).</p></sec><sec id="S15"><title>Discussion</title><p id="P19">Considering all patients regardless of their place of residence, our previous study, using the conventional and rather restrictive EORTC/MSG diagnostic criteria, revealed no significant changes to the institutional mould infection landscape after hurricane Harvey.<sup><xref rid="R2" ref-type="bibr">2</xref></sup> However, institution-wide data, including patients from non-affected areas, may &#x0201c;dilute&#x0201d; the trends and lack the granularity to identify subtle changes in IMI epidemiology in patient from areas impacted by floodwater damage. Therefore, the present study was uniquely restricted to patients from Harvey-affected counties, that is, counties qualifying for disaster assistance.<sup><xref rid="R3" ref-type="bibr">3</xref></sup> In this cohort, we indeed found a significantly increased number of mould-positive cultures in the year following the hurricane compared with pre-Harvey data. However, although the incidence rates of proven/probable IMIs and mcIMIs slightly increased after the hurricane, this trend did not reach statistical significance. Instead, 49% of the mould-positive cultures in patients from Harvey-affected counties were not associated with clinical correlates meeting either the conventional EORTC/MSG definition or the mcIMI definition. As most mould-positive cultures without a clinical correlate were obtained from respiratory materials (76%), we hypothesize that the increase in mould-positive cultures post-Harvey is primarily due to asymptomatic colonization of respiratory epithelia.</p><p id="P20">Historic data providing a clear link between residential mould exposure in post-disaster settings, airway colonization, and IMI events are scarce. Despite high levels of mould infestation immediately following hurricanes Katrina and Rita in 2005,<sup><xref rid="R5" ref-type="bibr">5</xref>&#x02013;<xref rid="R6" ref-type="bibr">6</xref></sup> there has been no evidence of elevated IMI incidence rates in exposed patient cohorts;<sup><xref rid="R6" ref-type="bibr">6</xref>&#x02013;<xref rid="R7" ref-type="bibr">7</xref></sup> however, transient asymptomatic airway colonization with Mucorales was seen in some residents of floodwater-damaged buildings.<sup><xref rid="R8" ref-type="bibr">8</xref></sup> A related observation was made for <italic toggle="yes">Aspergillus</italic>- and Basidiomycetes-positive sputum cultures after a tsunami in East Japan.<sup><xref rid="R9" ref-type="bibr">9</xref></sup> In contrast, our breakdown of positive cultures did not reveal major shifts or a selective predominance of causative genera post-Harvey (<xref rid="F3" ref-type="fig">Fig. 3A</xref>), which might be due to the much larger catchment area of our patients compared to the cited studies.</p><p id="P21">Of note, floodwater-damaged buildings can remain a source of increased exposure to pathogenic moulds even after mould remediation activities.<sup><xref rid="R10" ref-type="bibr">10</xref></sup> Therefore, long-term surveillance programs are warranted in Harvey-affected areas for both, IMIs in immunocom-promised populations and non-infectious respiratory hypersensitivity syndromes (e. g., mould-associated asthma) that were seen after previous geo-meteorological disasters.<sup><xref rid="R7" ref-type="bibr">7</xref></sup> As discussed previously,<sup><xref rid="R2" ref-type="bibr">2</xref></sup> there might also be a risk for delayed emergence of unusual mould pathogens such as the dimorphic fungus <italic toggle="yes">Coccidioides immitis</italic> in flooded areas.<sup><xref rid="R11" ref-type="bibr">11</xref></sup></p><p id="P22">In addition to increased numbers of mould-positive cultures, we observed a signal of worse outcomes in patients from Harvey-affected counties developing (mc)IMIs after the hurricane. While 42-day all-cause mortality did not significantly differ depending on the DOI, patients developing (mc)IMIs post-Harvey had significantly higher in-hospital mortality and tended to have higher ICU admission rates than patients with IMIs pre-Harvey. Although univariate analyses ruled out a significant impact of many important confounders (e. g., causative pathogens, sites of infection, cytopenia, underlying cancer diagnoses, and immunosuppressive therapies), the power of these analyses was limited, and meaningful multivariate analysis was not feasible due to the small sample size. Nonetheless, the observed trend toward worse outcomes in patients developing IMIs after hurricane Harvey is intriguing and the many dynamic and interrelated factors that could contribute to this observation deserve further study. One the one hand, it would be conceivable that increased colonization driven by extensive exposures increases the risk for severe IMI manifestations due to the high fungal burden.<sup><xref rid="R12" ref-type="bibr">12</xref></sup> On the other hand, residential exposure to moulds commonly found after water intrusion can trigger alterations in mould-reactive immune responses, especially elevated type&#x02013;2 T-helper cell responses<sup><xref rid="R13" ref-type="bibr">13</xref>&#x02013;<xref rid="R14" ref-type="bibr">14</xref></sup> that are considered non-protective and might contribute to immune pathology.<sup><xref rid="R15" ref-type="bibr">15</xref></sup> Furthermore, floodwater-damaged housing can be a reservoir of moulds producing mycotoxins<sup><xref rid="R10" ref-type="bibr">10</xref></sup> that have immunosuppressive properties and were shown to modulate host responses to invasive infection;<sup><xref rid="R16" ref-type="bibr">16</xref></sup> however, the clinical significance of this hypothesis remains to be established.</p><p id="P23">Our retrospective monocentric study has several limitations. While the FEMA assistance level<sup><xref rid="R3" ref-type="bibr">3</xref></sup> provides an at-large surrogate of a county&#x02019;s devastation by the hurricane and subsequent flooding, our study design did not facilitate correlation of the patients&#x02019; individual risk for mould exposure (e.g., participation in mould remediation or home reconstruction activities) and the incidence of mould-positive cultures or IMIs. Furthermore, the denominators used for incidence density calculations (<xref rid="F2" ref-type="fig">Fig. 2</xref>) were based on the institution-wide patient census since data restricted to patients living in Harvey-affected counties were not available. However, as there was no evidence for a significant shift in institutional patient catchment areas during the 2-year study period, this limitation likely has a minor impact on the validity of our analyses and conclusions. Similarly, the institutional laboratory information system did not facilitate a determination of the total number of mould cultures ordered from patients residing in Harvey-affected counties. We have previously reported that neither the number of mould cultures ordered institution-wide nor their positivity rate were significantly different before and after the hurricane.<sup><xref rid="R2" ref-type="bibr">2</xref></sup> However, in the absence of a culture census for patients from affected counties, our data do not allow us to determine whether the significantly higher post-Harvey incidence of positive cultures in patients from affected areas is driven by an increased number of cultures ordered, an increased culture positivity rate, or a combination of both. Furthermore, the relevance of individual pathogens as colonizers versus contaminants can be difficult to distinguish in the absence of a clinical correlate. For example, <italic toggle="yes">Aspergillus niger</italic> is known as a common colonizer of respiratory epithelia<sup><xref rid="R17" ref-type="bibr">17</xref></sup> and it is also a common contaminant at the MDACC Microbiology Laboratory. In addition, the uncommon saprophytic moulds are common colonizers and rarely true pathogens, even in high-risk cancer patients.<sup><xref rid="R18" ref-type="bibr">18</xref></sup> In order to examine these potential confounders in a sufficiently powered analysis and to evaluate the generalizability of our findings to other patient populations including patients with non-cancer-related predisposing factors for IMIs (e. g., patients with metabolic disorders such as diabetes mellitus), multi-centre data would be needed. Similarly, the mcIMI definition itself remains to be studied in multi-centre settings.</p><p id="P24">In summary, despite limitations, our unique study provides significant insights into the epidemiology of mould-positive cultures and IMI events after a devastating hurricane causing widespread flooding. Employing both, conventional EORTC/MSG definitions and a broader mcIMI case definition that considers therapeutic-intent antifungal drug prescription, our results corroborate the previously published observation that hurricane Harvey did not cause significant changes in IMI incidence and aetiological mould genera at MDACC.<sup><xref rid="R2" ref-type="bibr">2</xref></sup> The increased recovery of moulds from &#x02013; predominantly respiratory &#x02013; cultures in patients living in Harvey-affected counties likely reflects increased airway colonization and points to a need for long-term surveillance efforts, including non-infectious mould-associated diseases.<sup><xref rid="R19" ref-type="bibr">19</xref></sup> Lastly, we found that increased detection of moulds was a marker of poor outcomes of IMI events in patients from Harvey-affected counties. Altogether, these results emphasize the importance of risk awareness, enhanced mould prevention strategies,<sup><xref rid="R20" ref-type="bibr">20</xref></sup> and improved clinical management of IMIs in high-risk patients after geo-meteorological disasters.</p></sec><sec sec-type="supplementary-material" id="SM1"><title>Supplementary Material</title><supplementary-material id="SD1" position="float" content-type="local-data"><label>Supplementary material</label><media xlink:href="NIHMS1974200-supplement-Supplementary_material.docx" id="d66e502" position="anchor"/></supplementary-material></sec></body><back><ack id="S16"><title>Acknowledgment</title><p id="P25">This study was funded by the United States Centers for Disease Control and Prevention, Mycotic Diseases Branch (contract number 75D30119C05279). A part of this study was further supported by the Robert C. Hickey Chair in Clinical Care endowment to DPK.</p></ack><fn-group><fn fn-type="COI-statement" id="FN1"><p id="P26">Declaration of Competing Interest</p><p id="P27">DPK reports honoraria and research support from Gilead Sciences, received consultant fees from Astellas Pharma, Merck, and Gilead Sciences, and is a member of the Data Review Committee of Cidara Therapeutics, AbbVie, and the Mycoses Study Group. All other authors report no conflicts of interest.</p></fn><fn id="FN2"><p id="P28">Supplementary materials</p><p id="P29">Supplementary material associated with this article can be found, in the online version, at doi:<ext-link xlink:href="10.1016/j.jinf.2022.03.009" ext-link-type="doi">10.1016/j.jinf.2022.03.009</ext-link>.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><name><surname>Chow</surname><given-names>NA</given-names></name>, <name><surname>Toda</surname><given-names>M</given-names></name>, <name><surname>Pennington</surname><given-names>AF</given-names></name>, <name><surname>Anassi</surname><given-names>E</given-names></name>, <name><surname>Atmar</surname><given-names>RL</given-names></name>, <name><surname>Cox-Ganser</surname><given-names>JM</given-names></name>, <etal/>
<article-title>Hurricane-associated mold exposures among patients at risk for invasive mold infections after hurricane Harvey - Houston, Texas</article-title>. <source>MMWR Morb Mortal Wkly Rep. 2019</source>
<year>2017</year>;<volume>68</volume>(<issue>21</issue>):<fpage>469</fpage>&#x02013;<lpage>73</lpage>.</mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><name><surname>Kontoyiannis</surname><given-names>DP</given-names></name>, <name><surname>Shah</surname><given-names>EC</given-names></name>, <name><surname>Wurster</surname><given-names>S</given-names></name>, <name><surname>Aitken</surname><given-names>SL</given-names></name>, <name><surname>Graviss</surname><given-names>L</given-names></name>, <name><surname>Raad</surname><given-names>II</given-names></name>, <etal/>
<article-title>Culture-documented invasive mold infections at MD Anderson cancer center in Houston, Texas, pre- and post-hurricane Harvey</article-title>. <source>Open Forum Infect Dis</source>
<year>2019</year>;<volume>6</volume>(<issue>4</issue>):<fpage>ofz138</fpage>.<pub-id pub-id-type="pmid">31024975</pub-id>
</mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="webpage"><comment><ext-link xlink:href="https://gis.fema.gov/maps/dec_4332.pdf" ext-link-type="uri">https://gis.fema.gov/maps/dec_4332.pdf</ext-link></comment> (<date-in-citation>last accessed on July 22, 2021</date-in-citation>)</mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><name><surname>Donnelly</surname><given-names>JP</given-names></name>, <name><surname>Chen</surname><given-names>SC</given-names></name>, <name><surname>Kauffman</surname><given-names>CA</given-names></name>, <name><surname>Steinbach</surname><given-names>WJ</given-names></name>, <name><surname>Baddley</surname><given-names>JW</given-names></name>, <name><surname>Verweij</surname><given-names>PE</given-names></name>, <etal/>
<article-title>Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium</article-title>. <source>Clin Infect Dis</source>
<year>2020</year>;<volume>71</volume>(<issue>6</issue>):<fpage>1367</fpage>&#x02013;<lpage>76</lpage>.</mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><name><surname>Chew</surname><given-names>GL</given-names></name>, <name><surname>Wilson</surname><given-names>J</given-names></name>, <name><surname>Rabito</surname><given-names>FA</given-names></name>, <name><surname>Grimsley</surname><given-names>F</given-names></name>, <name><surname>Iqbal</surname><given-names>S</given-names></name>, <name><surname>Reponen</surname><given-names>T</given-names></name>, <name><surname>Muilenberg</surname><given-names>ML</given-names></name>, <name><surname>Thorne</surname><given-names>PS</given-names></name>, <name><surname>Dearborn</surname><given-names>DG</given-names></name>, <name><surname>Morley</surname><given-names>RL</given-names></name>. <article-title>Mold and endotoxin levels in the aftermath of Hurricane Katrina: a pilot project of homes in New Orleans undergoing renovation</article-title>. <source>Environ Health Perspect</source>
<year>2006</year>;<volume>114</volume>(<issue>12</issue>):<fpage>1883</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><name><surname>Benedict</surname><given-names>K</given-names></name>, <name><surname>Park</surname><given-names>BJ</given-names></name>. <article-title>Invasive fungal infections after natural disasters</article-title>. <source>Emerg Infect Dis</source>
<year>2014</year>;<volume>20</volume>(<issue>3</issue>):<fpage>349</fpage>&#x02013;<lpage>55</lpage>.</mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><name><surname>Barbeau</surname><given-names>DN</given-names></name>, <name><surname>Grimsley</surname><given-names>LF</given-names></name>, <name><surname>White</surname><given-names>LE</given-names></name>, <name><surname>El-Dahr</surname><given-names>JM</given-names></name>, <name><surname>Lichtveld</surname><given-names>M</given-names></name>. <article-title>Mold exposure and health effects following hurricanes Katrina and Rita</article-title>. <source>Annu Rev Public Health</source>
<year>2010</year>;<volume>31</volume>:<fpage>165</fpage>&#x02013;<lpage>78</lpage>
<comment>1 p following 178.</comment></mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><name><surname>Rao</surname><given-names>CY</given-names></name>, <name><surname>Kurukularatne</surname><given-names>C</given-names></name>, <name><surname>Garcia-Diaz</surname><given-names>JB</given-names></name>, <name><surname>Kemmerly</surname><given-names>SA</given-names></name>, <name><surname>Reed</surname><given-names>D</given-names></name>, <name><surname>Fridkin</surname><given-names>SK</given-names></name>, <etal/>
<article-title>Implications of detecting the mold Syncephalastrum in clinical specimens of New Orleans residents after Hurricanes Katrina and Rita</article-title>. <source>J Occup Environ Med</source>
<year>2007</year>;<volume>49</volume>(<issue>4</issue>):<fpage>411</fpage>&#x02013;<lpage>16</lpage>.</mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><name><surname>Ogawa</surname><given-names>H</given-names></name>, <name><surname>Fujimura</surname><given-names>M</given-names></name>, <name><surname>Takeuchi</surname><given-names>Y</given-names></name>, <name><surname>Makimura</surname><given-names>K</given-names></name>. <article-title>Chronic cough in a tsunami-affected town</article-title>. <source>Pulm Pharmacol Ther</source>
<year>2012</year>;<volume>25</volume>(<issue>1</issue>):<fpage>11</fpage>.</mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><name><surname>Jak&#x00161;i&#x00107;</surname><given-names>D</given-names></name>, <name><surname>Serti&#x00107;</surname><given-names>M</given-names></name>, <name><surname>Kocsub&#x000e9;</surname><given-names>S</given-names></name>, <name><surname>Kova&#x0010d;evi&#x00107;</surname><given-names>I</given-names></name>, <name><surname>Kifer</surname><given-names>D</given-names></name>, <name><surname>Mornar</surname><given-names>A</given-names></name>, <name><surname>Nigovi&#x00107;</surname><given-names>B</given-names></name>, <name><surname>&#x00160;egvi&#x00107; Klari&#x00107;</surname><given-names>M</given-names></name>. <article-title>Post-flood impacts on occurrence and distribution of mycotoxin-producing aspergilli from the sections Circumdati, Flavi, and Nigri in indoor environment</article-title>. <source>J Fungi (Basel)</source>
<year>2020</year>;<volume>6</volume>(<issue>4</issue>):<fpage>282</fpage>.</mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><name><surname>Comrie</surname><given-names>AC</given-names></name>. <article-title>Climate factors influencing coccidioidomycosis seasonality and outbreaks</article-title>. <source>Environ Health Perspect</source>
<year>2005</year>;<volume>113</volume>(<issue>6</issue>):<fpage>688</fpage>&#x02013;<lpage>92</lpage>.</mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><name><surname>Gago</surname><given-names>S</given-names></name>, <name><surname>Denning</surname><given-names>DW</given-names></name>, <name><surname>Bowyer</surname><given-names>P</given-names></name>. <article-title>Pathophysiological aspects of Aspergillus colonization in disease</article-title>. <source>Med Mycol</source>
<year>2019</year>;<volume>57</volume>(<issue>Supplement_2</issue>):<fpage>S219</fpage>&#x02013;<lpage>27</lpage>.</mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><name><surname>Page</surname><given-names>L</given-names></name>, <name><surname>Weis</surname><given-names>P</given-names></name>, <name><surname>M&#x000fc;ller</surname><given-names>T</given-names></name>, <name><surname>Dittrich</surname><given-names>M</given-names></name>, <name><surname>Lazariotou</surname><given-names>M</given-names></name>, <name><surname>Dragan</surname><given-names>M</given-names></name>, <name><surname>Waaga-Gasser</surname><given-names>AM</given-names></name>, <name><surname>Helm</surname><given-names>J</given-names></name>, <name><surname>Dandekar</surname><given-names>T</given-names></name>, <name><surname>Einsele</surname><given-names>H</given-names></name>, <name><surname>L&#x000f6;ffler</surname><given-names>J</given-names></name>, <name><surname>Ullmann</surname><given-names>AJ</given-names></name>, <name><surname>Wurster</surname><given-names>S</given-names></name>. <article-title>Evaluation of Aspergillus and Mucorales specific T-cells and peripheral blood mononuclear cell cytokine signatures as biomarkers of environmental mold exposure</article-title>. <source>Int J Med Microbiol</source>
<year>2018</year>;<volume>308</volume>(<issue>8</issue>):<fpage>1018</fpage>&#x02013;<lpage>26</lpage>.</mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><name><surname>Rosenblum Lichtenstein</surname><given-names>JH</given-names></name>, <name><surname>Molina</surname><given-names>RM</given-names></name>, <name><surname>Donaghey</surname><given-names>TC</given-names></name>, <name><surname>Hsu</surname><given-names>YH</given-names></name>, <name><surname>Mathews</surname><given-names>JA</given-names></name>, <name><surname>Kasahara</surname><given-names>DI</given-names></name>, <name><surname>Park</surname><given-names>JA</given-names></name>, <name><surname>Bordini</surname><given-names>A</given-names></name>, <name><surname>Godleski</surname><given-names>JJ</given-names></name>, <name><surname>Gillis</surname><given-names>BS</given-names></name>, <name><surname>Brain</surname><given-names>JD</given-names></name>. <article-title>Repeated mouse lung exposures to stachybotrys chartarum shift immune response from type 1 to type 2</article-title>. <source>Am J Respir Cell Mol Biol</source>
<year>2016</year>;<volume>55</volume>(<issue>4</issue>):<fpage>521</fpage>&#x02013;<lpage>31</lpage>.</mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><name><surname>McDermott</surname><given-names>AJ</given-names></name>, <name><surname>Klein</surname><given-names>BS</given-names></name>. <article-title>Helper T-cell responses and pulmonary fungal infections</article-title>. <source>Immunology</source>
<year>2018</year>;<volume>155</volume>(<issue>2</issue>):<fpage>155</fpage>&#x02013;<lpage>63</lpage>.</mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><name><surname>Kamei</surname><given-names>K</given-names></name>, <name><surname>Watanabe</surname><given-names>A</given-names></name>. <article-title>Aspergillus mycotoxins and their effect on the host</article-title>. <source>Med Mycol</source>
<year>2005</year>;<volume>43</volume>(<issue>Suppl 1</issue>):<fpage>S95</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="journal"><name><surname>Warris</surname><given-names>A</given-names></name>, <name><surname>Verweij</surname><given-names>PE</given-names></name>. <article-title>Clinical implications of environmental sources for aspergillus</article-title>. <source>Med Mycol</source>
<year>2005</year>;<volume>43</volume>(<issue>Suppl 1</issue>):<fpage>S59</fpage>&#x02013;<lpage>65</lpage>.</mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><name><surname>Lionakis</surname><given-names>MS</given-names></name>, <name><surname>Kontoyiannis</surname><given-names>DP</given-names></name>. <article-title>The significance of isolation of saprophytic molds from the lower respiratory tract in patients with cancer</article-title>. <source>Cancer</source>
<year>2004</year>;<volume>100</volume>(<issue>1</issue>):<fpage>165</fpage>&#x02013;<lpage>72</lpage>.</mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><name><surname>Saporta</surname><given-names>D</given-names></name>, <name><surname>Hurst</surname><given-names>D</given-names></name>. <article-title>Increased sensitization to mold allergens measured by intradermal skin testing following hurricanes</article-title>. <source>J Environ Public Health</source>
<year>2017</year>;<volume>2017</volume>:<fpage>2793820</fpage>.</mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal"><name><surname>Brandt</surname><given-names>M</given-names></name>, <name><surname>Brown</surname><given-names>C</given-names></name>, <name><surname>Burkhart</surname><given-names>J</given-names></name>, <name><surname>Burton</surname><given-names>N</given-names></name>, <name><surname>Cox-Ganser</surname><given-names>J</given-names></name>, <name><surname>Damon</surname><given-names>S</given-names></name>, <etal/>
<article-title>Mold prevention strategies and possible health effects in the aftermath of hurricanes and major floods</article-title>. <source>MMWR Recomm Rep</source>
<year>2006</year>;<volume>55</volume>(<issue>RR&#x02013;8</issue>):<fpage>1</fpage>&#x02013;<lpage>27</lpage>.</mixed-citation></ref></ref-list></back><floats-group><fig position="float" id="F1"><label>Fig. 1.</label><caption><p id="P30">Flow chart for case adjudication.</p></caption><graphic xlink:href="nihms-1974200-f0001" position="float"/></fig><fig position="float" id="F2"><label>Fig. 2.</label><caption><p id="P31">Numbers of cases identified by classification and date of incidence (DOI).</p></caption><graphic xlink:href="nihms-1974200-f0002" position="float"/></fig><fig position="float" id="F3"><label>Fig. 3.</label><caption><p id="P32">Incidence rates of mould-positive cultures and IMI events pre- and post-Harvey. (A) Breakdown of incidence rates of mould positive cultures in patients from Harvey-affected areas per 1000 hospital admissions and per 100,000 inpatient days before (<italic toggle="yes">n</italic> = 36) and after (<italic toggle="yes">n</italic> = 67) hurricane Harvey by causative genus/order. (B) Comparison of IMI incidence rates before and after hurricane Harvey. (C) Incidence rates of mould-positive cultures without a clinical correlate, i.e. cases not meeting the IMI definitions, before and after hurricane Harvey. Chi-square test.</p></caption><graphic xlink:href="nihms-1974200-f0003" position="float"/></fig><fig position="float" id="F4"><label>Fig. 4.</label><caption><p id="P33">42-day Kaplan-Meier survival curves of patients with proven/probable IMI (EORTC/MSG definition) or mcIMI (CDC definition) before and after hurricane Harvey. Black ticks indicate censored data. Mantel-Cox log-rank test. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)</p></caption><graphic xlink:href="nihms-1974200-f0004" position="float"/></fig><table-wrap position="float" id="T1" orientation="landscape"><label>Table 1</label><caption><p id="P34">Host and clinical criteria applied for case adjudication.</p></caption><table frame="hsides" rules="none"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Category</th><th align="left" valign="top" rowspan="1" colspan="1">Criteria</th></tr><tr><th colspan="2" align="left" valign="top" rowspan="1">
<hr/>
</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">EORTC/MSG host Factors</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02022; Recent history of neutropenia (ANC &#x0003c; 500/&#x003bc;L for &#x0003e; 10 d) temporally related to the onset of invasive fungal disease<break/>&#x02022; Active hematologic malignancy<break/>&#x02022; Receipt of an allogeneic stem cell transplant<break/>&#x02022; Receipt of a solid organ transplant<break/>&#x02022; Prolonged use of corticosteroids at a therapeutic dose of &#x02265;0.3 mg/kg corticosteroids for &#x02265;3 weeks in the past 60 d<break/>&#x02022; Treatment with other recognized T-cell immunosuppressants (e.g., calcineurin inhibitors or immunosuppressive nucleoside analogues) during the past 90 d<break/>&#x02022; Treatment with recognized B-cell immunosuppressants (e.g., ibrutinib)<break/>&#x02022; Inherited severe immunodeficiency (such as chronic granulomatous disease, STAT3 deficiency, or severe combined immunodeficiency)<break/>&#x02022; Acute graft-versus-host disease grade III or IV involving the gut, lungs, or liver that is refractory to first-line treatment with steroids</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Non-EORTC/MSG<break/>Host Factors</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02022; Other immunosuppressive or chemotherapeutic medications in the 90 d before DOI<break/>&#x02022; Total body irradiation in the 90 d before DOI<break/>&#x02022; Lymphopenia ( &#x02264;1000/&#x003bc;L) in the 90 d before DOI<break/>&#x02022; Acquired immunodeficiency syndrome (CD4 <sup>+</sup> T-helper cells &#x0003c; 200/&#x003bc;L)<break/>&#x02022; B cell lymphoma<break/>&#x02022; New cancer diagnosis in the 90 d before DOI, with or without therapy<break/>&#x02022; Active cancer: cancer patient on chemotherapy at time of DOI, or diagnosed in the past 6 months, or cancer noted to be recurrent, metastatic or inoperable<break/>&#x02022; Autologous stem cell transplant<break/>&#x02022; Temporal arteritis or scleroderma<break/>&#x02022; Chronic obstructive pulmonary disease<break/>&#x02022; Hepatitis C, cirrhosis, and/or alcoholism<break/>&#x02022; X-linked adrenoleukodystrophy<break/>&#x02022; Uncontrolled diabetes mellitus (HbA1c &#x0003e; 8%)<break/>&#x02022; End stage renal disease<break/>&#x02022; Burn<break/>&#x02022; Recent eye surgery</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">EORTC/MSG clinical Factors</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02022; Pulmonary aspergillosis: The presence of 1 of the following 4 patterns on CT: a) Dense, well-circumscribed lesions(s) with or without a halo sign, b) air crescent sign, c) cavity, d) wedge-shaped and segmental or lobar consolidation<break/>&#x02022; Other pulmonary mould infections: Same criteria as for pulmonary aspergillosis but also including a reverse halo sign<break/>&#x02022; Tracheobronchitis: Tracheobronchial ulceration, nodule, pseudomembrane, plaque, or eschar seen in bronchoscopy<break/>&#x02022; Sino-nasal diseases: Acute localized pain (including pain radiating to the eye), nasal ulcer with black eschar, or lesions extending from the paranasal sinus across bony barriers (e.g., into the orbit)<break/>&#x02022; Central nervous system infection: 1 of the following 2 signs: a) Focal lesions on imaging, b) Meningeal enhancement on magnetic resonance imaging or CT</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Non-EORTC/MSG clinical factors</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02022; Lower respiratory tract: Cavity on X-ray; focal opacity, tree-in-bud micronodularity/opacity, ground glass opacity, nodular opacity, patchy opacity, consolidation, nodule, mass lesions, pleural effusions, or other abnormal pulmonary CT findings not specifically included in the MSG definition; pneumothorax (lung collapse); clinical signs of pneumonia<break/>&#x02022; Sinonasal infection: Manifestations not meeting MSG definition or including other signs, e.g., orbital cellulitis<break/>&#x02022; Wound infections: Burns, open fracture, necrotic tissue, and/or ulcers</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p id="P35"><underline>Abbreviations:</underline> ANC = absolute neutrophil count, CD = cluster of differentiation, CT = computed tomography, <italic toggle="yes">d</italic> = days, DOI = date of incidence, EORTC/MSG = European Organization for Research and Treatment of Cancer &#x00026; Mycosis Study Group, STAT3 = signal transducer and activator of transcription 3.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T2" orientation="landscape"><label>Table 2</label><caption><title>Comparison of patient demographics, predisposing factors, treatment, and outcomes by final case determination.</title><p id="P36">Unless specified otherwise in the &#x0201c;characteristics&#x0201d; column, numbers of patients and percentages (%) are provided. Significant p-values for 3-group comparisons are highlighted in bold. Significant p-values for pairwise post tests are indicated by the following symbols: # proven/probable IMI (EORTC/MSG definition) versus mcIMI, $ proven/probable IMI versus patients not meeting IMI criteria, &#x000a7; mcIMI versus patients not meeting IMI criteria.</p></caption><table frame="hsides" rules="none"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Characteristics</th><th align="center" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">Proven/probable IMI <italic toggle="yes">N</italic> = 20</th><th align="center" valign="top" rowspan="1" colspan="1">mcIMI (CDC definition) <italic toggle="yes">N</italic> = 37</th><th align="center" valign="top" rowspan="1" colspan="1">Not meeting IMI criteria <italic toggle="yes">N</italic> = 46</th><th align="center" valign="top" rowspan="1" colspan="1">P-value</th><th align="center" valign="top" rowspan="1" colspan="1">Pairwise comp.</th></tr><tr><th colspan="7" align="left" valign="top" rowspan="1">
<hr/>
</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Age</td><td align="left" valign="top" rowspan="1" colspan="1">Median (range)</td><td align="left" valign="top" rowspan="1" colspan="1">58 (23&#x02013;84)</td><td align="left" valign="top" rowspan="1" colspan="1">61 (33&#x02013;89)</td><td align="left" valign="top" rowspan="1" colspan="1">68 (26&#x02013;90)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x0003c; 0.01</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">$</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gender</td><td align="left" valign="top" rowspan="1" colspan="1">Male</td><td align="left" valign="top" rowspan="1" colspan="1">14 (70)</td><td align="left" valign="top" rowspan="1" colspan="1">23 (62)</td><td align="left" valign="top" rowspan="1" colspan="1">24 (52)</td><td align="left" valign="top" rowspan="1" colspan="1">0.36</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Female</td><td align="left" valign="top" rowspan="1" colspan="1">6 (30)</td><td align="left" valign="top" rowspan="1" colspan="1">14 (38)</td><td align="left" valign="top" rowspan="1" colspan="1">22 (48)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cancer diagnoses<sup><xref rid="TFN2" ref-type="table-fn">a</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">Active cancer within the last 2 years</td><td align="left" valign="top" rowspan="1" colspan="1">20 (100)</td><td align="left" valign="top" rowspan="1" colspan="1">37 (100)</td><td align="left" valign="top" rowspan="1" colspan="1">44 (96)</td><td align="left" valign="top" rowspan="1" colspan="1">0.68</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Leukaemia/MDS</td><td align="left" valign="top" rowspan="1" colspan="1">16 (80)</td><td align="left" valign="top" rowspan="1" colspan="1">17 (46)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (9)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x0003c; 0.001</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">#, $, &#x000a7;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Lymphoma/myeloma</td><td align="left" valign="top" rowspan="1" colspan="1">2 (10)</td><td align="left" valign="top" rowspan="1" colspan="1">11 (30)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (15)</td><td align="left" valign="top" rowspan="1" colspan="1">0.12</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Solid tumour</td><td align="left" valign="top" rowspan="1" colspan="1">3 (15)</td><td align="left" valign="top" rowspan="1" colspan="1">10 (27)</td><td align="left" valign="top" rowspan="1" colspan="1">36 (78)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x0003c; 0.001</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">$, &#x000a7;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HSCT</td><td align="left" valign="top" rowspan="1" colspan="1">Any HSCT</td><td align="left" valign="top" rowspan="1" colspan="1">4 (20)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (19)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (4)</td><td align="left" valign="top" rowspan="1" colspan="1">0.06</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Allogenic</td><td align="left" valign="top" rowspan="1" colspan="1">4/4 (100)</td><td align="left" valign="top" rowspan="1" colspan="1">3/7 (43)</td><td align="left" valign="top" rowspan="1" colspan="1">0/2 (0)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Autologous</td><td align="left" valign="top" rowspan="1" colspan="1">0/4 (0)</td><td align="left" valign="top" rowspan="1" colspan="1">4/7 (57)</td><td align="left" valign="top" rowspan="1" colspan="1">2/2 (100)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GvHD</td><td align="left" valign="top" rowspan="1" colspan="1">(% amongst allo-HSCT recipients)</td><td align="left" valign="top" rowspan="1" colspan="1">1/4 (25)</td><td align="left" valign="top" rowspan="1" colspan="1">1/3 (33)</td><td align="left" valign="top" rowspan="1" colspan="1">n/a</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Neutropenia</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c; 500/&#x003bc;L for &#x0003e; 10 d within the last 30 d</td><td align="left" valign="top" rowspan="1" colspan="1">3 (15)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (3)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x0003c; 0.001</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">#, $</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c; 500/ <italic toggle="yes">&#x003bc;</italic>L within the last 30 d</td><td align="left" valign="top" rowspan="1" colspan="1">10 (50)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (16)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (9)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">History of neutropenia</td><td align="left" valign="top" rowspan="1" colspan="1">3 (15)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (11)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (4)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">No neutropenia</td><td align="left" valign="top" rowspan="1" colspan="1">4 (20)</td><td align="left" valign="top" rowspan="1" colspan="1">26 (70)</td><td align="left" valign="top" rowspan="1" colspan="1">40 (87)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lymphopenia</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c; 1000/&#x003bc;L within the last 30 d</td><td align="left" valign="top" rowspan="1" colspan="1">10 (50)</td><td align="left" valign="top" rowspan="1" colspan="1">18 (49)</td><td align="left" valign="top" rowspan="1" colspan="1">11(24)</td><td align="left" valign="top" rowspan="1" colspan="1">0.11</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">History of lymphopenia</td><td align="left" valign="top" rowspan="1" colspan="1">4 (20)</td><td align="left" valign="top" rowspan="1" colspan="1">8 (22)</td><td align="left" valign="top" rowspan="1" colspan="1">11 (24)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">No lymphopenia</td><td align="left" valign="top" rowspan="1" colspan="1">6 (30)</td><td align="left" valign="top" rowspan="1" colspan="1">11 (30)</td><td align="left" valign="top" rowspan="1" colspan="1">24 (52)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diabetes mellitus</td><td align="left" valign="top" rowspan="1" colspan="1">Any type</td><td align="left" valign="top" rowspan="1" colspan="1">3 (15)</td><td align="left" valign="top" rowspan="1" colspan="1">9 (24)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (11)</td><td align="left" valign="top" rowspan="1" colspan="1">0.25</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Type 1</td><td align="left" valign="top" rowspan="1" colspan="1">0/3 (0)</td><td align="left" valign="top" rowspan="1" colspan="1">2/9 (22)</td><td align="left" valign="top" rowspan="1" colspan="1">0/5 (0)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Type 2</td><td align="left" valign="top" rowspan="1" colspan="1">3/3 (100)</td><td align="left" valign="top" rowspan="1" colspan="1">6/9 (67)</td><td align="left" valign="top" rowspan="1" colspan="1">5/5 (100)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Other</td><td align="left" valign="top" rowspan="1" colspan="1">0/3 (0)</td><td align="left" valign="top" rowspan="1" colspan="1">1/9 (11)</td><td align="left" valign="top" rowspan="1" colspan="1">0/5 (0)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">HbA1c &#x0003e; 8%</td><td align="left" valign="top" rowspan="1" colspan="1">1/3 (33)</td><td align="left" valign="top" rowspan="1" colspan="1">2/9 (22)</td><td align="left" valign="top" rowspan="1" colspan="1">1/5 (20)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003e; 0.99</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GCS</td><td align="left" valign="top" rowspan="1" colspan="1">Systemic GCS within the last 90 d</td><td align="left" valign="top" rowspan="1" colspan="1">16 (80)</td><td align="left" valign="top" rowspan="1" colspan="1">24 (65)</td><td align="left" valign="top" rowspan="1" colspan="1">19 (41)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x0003c; 0.01</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">$</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x0003e; 200 mg prednisolone eq. per day</td><td align="left" valign="top" rowspan="1" colspan="1">13/16 (81)</td><td align="left" valign="top" rowspan="1" colspan="1">19/24 (79)</td><td align="left" valign="top" rowspan="1" colspan="1">14/19 (74)</td><td align="left" valign="top" rowspan="1" colspan="1">0.85</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td colspan="2" align="left" valign="top" rowspan="1">Other immunosuppressive or cytotoxic therapies (last 90 d)</td><td align="left" valign="top" rowspan="1" colspan="1">8 (40)</td><td align="left" valign="top" rowspan="1" colspan="1">17 (46)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (9)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x0003c; 0.01</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">$, &#x000a7;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pathogen</td><td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">Aspergillus</italic> spp.</td><td align="left" valign="top" rowspan="1" colspan="1">4/19 (21)</td><td align="left" valign="top" rowspan="1" colspan="1">24/32 (75)</td><td align="left" valign="top" rowspan="1" colspan="1">29/45 (64)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x0003c; 0.001</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">#, $, &#x000a7;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">Fusarium</italic> spp.</td><td align="left" valign="top" rowspan="1" colspan="1">8/19 (42)</td><td align="left" valign="top" rowspan="1" colspan="1">1/32 (3)</td><td align="left" valign="top" rowspan="1" colspan="1">1/45 (2)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Mucorales</td><td align="left" valign="top" rowspan="1" colspan="1">5/19 (26)</td><td align="left" valign="top" rowspan="1" colspan="1">3/32 (9)</td><td align="left" valign="top" rowspan="1" colspan="1">0/45 (0)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Other</td><td align="left" valign="top" rowspan="1" colspan="1">2/19 (11)</td><td align="left" valign="top" rowspan="1" colspan="1">4/32 (13)</td><td align="left" valign="top" rowspan="1" colspan="1">15/45 (33)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Unknown</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Site of infection</td><td align="left" valign="top" rowspan="1" colspan="1">Lung</td><td align="left" valign="top" rowspan="1" colspan="1">4 (20)</td><td align="left" valign="top" rowspan="1" colspan="1">34 (92)</td><td align="left" valign="top" rowspan="1" colspan="1">n/a</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x0003c; 0.001</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">#</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Nasal/sinus</td><td align="left" valign="top" rowspan="1" colspan="1">5 (25)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="left" valign="top" rowspan="1" colspan="1">n/a</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Skin/soft tissue/wound</td><td align="left" valign="top" rowspan="1" colspan="1">8 (40)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (3)</td><td align="left" valign="top" rowspan="1" colspan="1">n/a</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Disseminated</td><td align="left" valign="top" rowspan="1" colspan="1">3 (15)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (5)</td><td align="left" valign="top" rowspan="1" colspan="1">n/a</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Mould-active antifungal therapy<sup><xref rid="TFN3" ref-type="table-fn">b</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">At least 1 antifungal drug</td><td align="left" valign="top" rowspan="1" colspan="1">19 (95)<sup><xref rid="TFN4" ref-type="table-fn">c</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">37 (100)</td><td align="left" valign="top" rowspan="1" colspan="1">12 (26)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x0003c; 0.001</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">$, &#x000a7;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Liposomal amphotericin B</td><td align="left" valign="top" rowspan="1" colspan="1">13 (65)</td><td align="left" valign="top" rowspan="1" colspan="1">13 (35)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (4)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x0003c; 0.001</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">#, $, &#x000a7;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Fluconazole<sup><xref rid="TFN5" ref-type="table-fn">d</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">3 (15)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (5)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (4)</td><td align="left" valign="top" rowspan="1" colspan="1">0.26</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Itraconazole</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (2)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003e; 0.99</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Posaconazole</td><td align="left" valign="top" rowspan="1" colspan="1">15 (75)</td><td align="left" valign="top" rowspan="1" colspan="1">23 (62)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (4)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x0003c; 0.001</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">$, &#x000a7;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Voriconazole</td><td align="left" valign="top" rowspan="1" colspan="1">6 (30)</td><td align="left" valign="top" rowspan="1" colspan="1">26 (70)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (9)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x0003c; 0.001</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">#, &#x000a7;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Isavuconazole</td><td align="left" valign="top" rowspan="1" colspan="1">8 (40)</td><td align="left" valign="top" rowspan="1" colspan="1">9 (24)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (2)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x0003c; 0.001</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">$, &#x000a7;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Echinocandins</td><td align="left" valign="top" rowspan="1" colspan="1">14 (70)</td><td align="left" valign="top" rowspan="1" colspan="1">16 (43)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (9)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x0003c; 0.001</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">$, &#x000a7;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Outcomes</td><td align="left" valign="top" rowspan="1" colspan="1">Hospitalization</td><td align="left" valign="top" rowspan="1" colspan="1">20 (100)</td><td align="left" valign="top" rowspan="1" colspan="1">32 (86)</td><td align="left" valign="top" rowspan="1" colspan="1">25 (54)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x0003c; 0.001</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">$, &#x000a7;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">ICU admission</td><td align="left" valign="top" rowspan="1" colspan="1">6 (30)</td><td align="left" valign="top" rowspan="1" colspan="1">20 (54)</td><td align="left" valign="top" rowspan="1" colspan="1">12 (26)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.03</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">&#x000a7;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Died in hospital</td><td align="left" valign="top" rowspan="1" colspan="1">7 (35)</td><td align="left" valign="top" rowspan="1" colspan="1">14 (38)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (15)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.05</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="TFN2"><label>a</label><p id="P37">five patients had two cancer diagnoses.</p></fn><fn id="TFN3"><label>b</label><p id="P38">does not include drugs that were initiated prior to the date of incidence and were given in prophylactic intention.</p></fn><fn id="TFN4"><label>c</label><p id="P39">(proven) IMI of one patient not receiving antifungal therapy was established post-mortem based on autopsy findings.</p></fn><fn id="TFN5"><label>d</label><p id="P40">fluconazole alone was only considered &#x0201c;mould-active antifungal therapy&#x0201d; when given for putative dimorphic fungal infections.</p></fn><fn id="TFN6"><p id="P41"><underline>Abbreviations:</underline> CDC = United States Centers for Disease Control and Prevention, comp. = comparison, <italic toggle="yes">d</italic> = days, eq = equivalent, GCS = glucocorticosteroids, GvHD = graft versus host disease, (allo-) HSCT = (allogenic) hematopoietic stem cell transplant, ICU = intensive care unit, IMI = invasive mould infection, mcIMI = modified clinical IMI definition, MDS = myelodysplastic syndrome, mg = milligrams.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T3" orientation="landscape"><label>Table 3</label><caption><title>Demographics, predisposing factors, and treatment by date of incidence, considering patients meeting either the proven or probable IMI definition (EORTC/MSG) or the mcIMI definition (CDC).</title><p id="P42">Unless specified otherwise in the &#x0201c;characteristics&#x0201d; column, numbers of patients and percentages (%) are provided. Significant p-values are highlighted in bold.</p></caption><table frame="hsides" rules="none"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">Pre-Harvey <italic toggle="yes">N</italic> = 23</th><th align="left" valign="top" rowspan="1" colspan="1">Post-Harvey <italic toggle="yes">N</italic> = 34</th><th align="left" valign="top" rowspan="1" colspan="1">P-value</th></tr><tr><th colspan="5" align="left" valign="top" rowspan="1">
<hr/>
</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Age</td><td align="left" valign="top" rowspan="1" colspan="1">Median (range)</td><td align="left" valign="top" rowspan="1" colspan="1">60 (23&#x02013;78)</td><td align="left" valign="top" rowspan="1" colspan="1">61 (25&#x02013;89)</td><td align="left" valign="top" rowspan="1" colspan="1">0.78</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gender</td><td align="left" valign="top" rowspan="1" colspan="1">Male</td><td align="left" valign="top" rowspan="1" colspan="1">17 (74)</td><td align="left" valign="top" rowspan="1" colspan="1">20 (59)</td><td align="left" valign="top" rowspan="1" colspan="1">0.24</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Female</td><td align="left" valign="top" rowspan="1" colspan="1">6 (26)</td><td align="left" valign="top" rowspan="1" colspan="1">14 (41)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cancer diagnoses <sup><xref rid="TFN7" ref-type="table-fn">a</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">Active cancer within the last 2 years</td><td align="left" valign="top" rowspan="1" colspan="1">23 (100)</td><td align="left" valign="top" rowspan="1" colspan="1">34 (100)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Leukaemia/MDS</td><td align="left" valign="top" rowspan="1" colspan="1">14 (61)</td><td align="left" valign="top" rowspan="1" colspan="1">19 (56)</td><td align="left" valign="top" rowspan="1" colspan="1">0.71</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Lymphoma/myeloma</td><td align="left" valign="top" rowspan="1" colspan="1">3 (13)</td><td align="left" valign="top" rowspan="1" colspan="1">10 (29)</td><td align="left" valign="top" rowspan="1" colspan="1">0.15</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Solid tumour</td><td align="left" valign="top" rowspan="1" colspan="1">6 (26)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (21)</td><td align="left" valign="top" rowspan="1" colspan="1">0.63</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HSCT</td><td align="left" valign="top" rowspan="1" colspan="1">Any HSCTAllogenicAutologous</td><td align="left" valign="top" rowspan="1" colspan="1">2 (9)</td><td align="left" valign="top" rowspan="1" colspan="1">9 (26)</td><td align="left" valign="top" rowspan="1" colspan="1">0.17</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Allogenic</td><td align="left" valign="top" rowspan="1" colspan="1">2/2 (100)</td><td align="left" valign="top" rowspan="1" colspan="1">5/9 (56)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Autologous</td><td align="left" valign="top" rowspan="1" colspan="1">0/2 (0)</td><td align="left" valign="top" rowspan="1" colspan="1">4/9 (44)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GvHD</td><td align="left" valign="top" rowspan="1" colspan="1">(% amongst allo-HSCT recipients)</td><td align="left" valign="top" rowspan="1" colspan="1">1/2 (50)</td><td align="left" valign="top" rowspan="1" colspan="1">1/5 (20)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Neutropenia</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c; 500/&#x003bc;L for &#x0003e; 10 d within the last 30 d</td><td align="left" valign="top" rowspan="1" colspan="1">3 (13)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (3)</td><td align="left" valign="top" rowspan="1" colspan="1">0.49</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c; 500/ <italic toggle="yes">&#x003bc;</italic>L within the last 30 d</td><td align="left" valign="top" rowspan="1" colspan="1">7 (30)</td><td align="left" valign="top" rowspan="1" colspan="1">9 (26)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">History of neutropenia</td><td align="left" valign="top" rowspan="1" colspan="1">3 (13)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (12)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">No neutropenia</td><td align="left" valign="top" rowspan="1" colspan="1">10 (43)</td><td align="left" valign="top" rowspan="1" colspan="1">20 (59)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lymphopenia</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c; 1000/ &#x003bc;L within the last 30 d</td><td align="left" valign="top" rowspan="1" colspan="1">13 (57)</td><td align="left" valign="top" rowspan="1" colspan="1">15 (44)</td><td align="left" valign="top" rowspan="1" colspan="1">0.17</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">History of lymphopenia</td><td align="left" valign="top" rowspan="1" colspan="1">2 (9)</td><td align="left" valign="top" rowspan="1" colspan="1">10 (29)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">No lymphopenia</td><td align="left" valign="top" rowspan="1" colspan="1">8 (35)</td><td align="left" valign="top" rowspan="1" colspan="1">9 (26)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diabetes mellitus</td><td align="left" valign="top" rowspan="1" colspan="1">Any type</td><td align="left" valign="top" rowspan="1" colspan="1">5 (22)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (21)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003e; 0.99</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Type 1</td><td align="left" valign="top" rowspan="1" colspan="1">1/5 (20)</td><td align="left" valign="top" rowspan="1" colspan="1">1/7 (14)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Type 2</td><td align="left" valign="top" rowspan="1" colspan="1">4/5 (80)</td><td align="left" valign="top" rowspan="1" colspan="1">5/7 (71)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Other</td><td align="left" valign="top" rowspan="1" colspan="1">0/5 (0)</td><td align="left" valign="top" rowspan="1" colspan="1">1/7 (14)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">HbA1c &#x0003e; 8%</td><td align="left" valign="top" rowspan="1" colspan="1">2/5 (40)</td><td align="left" valign="top" rowspan="1" colspan="1">1/7 (14)</td><td align="left" valign="top" rowspan="1" colspan="1">0.52</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GCS</td><td align="left" valign="top" rowspan="1" colspan="1">Systemic GCS within the last 90 d</td><td align="left" valign="top" rowspan="1" colspan="1">19 (83)</td><td align="left" valign="top" rowspan="1" colspan="1">21 (62)</td><td align="left" valign="top" rowspan="1" colspan="1">0.09</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x0003e; 200 mg prednisolone eq. per day</td><td align="left" valign="top" rowspan="1" colspan="1">17/19 (89)</td><td align="left" valign="top" rowspan="1" colspan="1">15/21 (71)</td><td align="left" valign="top" rowspan="1" colspan="1">0.24</td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1">Other immunosuppressive or cytotoxic therapies (last 90d)</td><td align="left" valign="top" rowspan="1" colspan="1">11 (48)</td><td align="left" valign="top" rowspan="1" colspan="1">14 (41)</td><td align="left" valign="top" rowspan="1" colspan="1">0.62</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pathogen</td><td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">Aspergillus</italic> spp.</td><td align="left" valign="top" rowspan="1" colspan="1">11/21 (52)</td><td align="left" valign="top" rowspan="1" colspan="1">17/30 (57)</td><td align="left" valign="top" rowspan="1" colspan="1">0.85</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">Fusarium</italic> spp.</td><td align="left" valign="top" rowspan="1" colspan="1">3/21 (14)</td><td align="left" valign="top" rowspan="1" colspan="1">6/30 (20)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Mucorales</td><td align="left" valign="top" rowspan="1" colspan="1">4/21 (19)</td><td align="left" valign="top" rowspan="1" colspan="1">4/30 (13)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Other</td><td align="left" valign="top" rowspan="1" colspan="1">3/21 (14)</td><td align="left" valign="top" rowspan="1" colspan="1">3/30 (10)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Unknown</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Site of infection</td><td align="left" valign="top" rowspan="1" colspan="1">Lung</td><td align="left" valign="top" rowspan="1" colspan="1">16 (70)</td><td align="left" valign="top" rowspan="1" colspan="1">22 (65)</td><td align="left" valign="top" rowspan="1" colspan="1">0.26</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Nasal/sinus</td><td align="left" valign="top" rowspan="1" colspan="1">2 (9)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (9)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Skin/soft tissue/wound</td><td align="left" valign="top" rowspan="1" colspan="1">5 (22)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (12)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Disseminated</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (15)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Mould-active antifungal therapy<sup><xref rid="TFN8" ref-type="table-fn">b</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">At least 1 antifungal drug</td><td align="left" valign="top" rowspan="1" colspan="1">23 (100)</td><td align="left" valign="top" rowspan="1" colspan="1">33 (97)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003e; 0.99</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Liposomal amphotericin B</td><td align="left" valign="top" rowspan="1" colspan="1">9 (39)</td><td align="left" valign="top" rowspan="1" colspan="1">17 (50)</td><td align="left" valign="top" rowspan="1" colspan="1">0.42</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Fluconazole<sup><xref rid="TFN9" ref-type="table-fn">c</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">1 (4)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (12)</td><td align="left" valign="top" rowspan="1" colspan="1">0.64</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Posaconazole</td><td align="left" valign="top" rowspan="1" colspan="1">16 (70)</td><td align="left" valign="top" rowspan="1" colspan="1">22 (65)</td><td align="left" valign="top" rowspan="1" colspan="1">0.70</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Voriconazole</td><td align="left" valign="top" rowspan="1" colspan="1">13 (57)</td><td align="left" valign="top" rowspan="1" colspan="1">19 (56)</td><td align="left" valign="top" rowspan="1" colspan="1">0.96</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Echinocandins</td><td align="left" valign="top" rowspan="1" colspan="1">11 (48)</td><td align="left" valign="top" rowspan="1" colspan="1">19 (56)</td><td align="left" valign="top" rowspan="1" colspan="1">0.55</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Outcomes</td><td align="left" valign="top" rowspan="1" colspan="1">Hospitalization</td><td align="left" valign="top" rowspan="1" colspan="1">22 (96)</td><td align="left" valign="top" rowspan="1" colspan="1">30 (88)</td><td align="left" valign="top" rowspan="1" colspan="1">0.64</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">ICU admission</td><td align="left" valign="top" rowspan="1" colspan="1">7 (30)</td><td align="left" valign="top" rowspan="1" colspan="1">19 (56)</td><td align="left" valign="top" rowspan="1" colspan="1">0.06</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Died in hospital</td><td align="left" valign="top" rowspan="1" colspan="1">4 (17)</td><td align="left" valign="top" rowspan="1" colspan="1">17 (50)</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.01</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Died within 42 days</td><td align="left" valign="top" rowspan="1" colspan="1">7 (30)</td><td align="left" valign="top" rowspan="1" colspan="1">15/33 (45)<sup><xref rid="TFN10" ref-type="table-fn">d</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">0.26</td></tr></tbody></table><table-wrap-foot><fn id="TFN7"><label>a</label><p id="P43">two patients had two cancer diagnoses.</p></fn><fn id="TFN8"><label>b</label><p id="P44">does not include drugs that were initiated prior to the date of incidence and were given in prophylactic intention.</p></fn><fn id="TFN9"><label>c</label><p id="P45">fluconazole alone was only considered &#x0201c;mould-active antifungal therapy&#x0201d; when given for putative dimorphic fungal infections.</p></fn><fn id="TFN10"><label>d</label><p id="P46">follow-up was lost for one patient before day 42.</p></fn><fn id="TFN11"><p id="P47"><underline>Abbreviations:</underline>
<italic toggle="yes">d</italic> = days, def = definition, eq = equivalent, GCS = glucocorticosteroids, GvHD = graft versus host disease, (allo-) HSCT = (allogenic) hematopoietic stem cell transplant, ICU = intensive care unit, IMI = invasive mould infection, MDS = myelodysplastic syndrome, mg = milligrams.</p></fn></table-wrap-foot></table-wrap></floats-group></article>